FABP5 is linked to breast cancer proliferation and resistance, whereas serum and tumor FABP4 levels were found to be significantly higher in BC patients than that of healthy controls and were positively connected with tumor size, aggressiveness and lymph node involvement [14,21,22,23,24]. Here, FABP5 is linked to breast carcinoma.